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Summary
Background
Circulating microRNAs are emerging as potential prognostic biomarkers for the
development of type 2 diabetes. However, microRNAs are also associated with
complications from impaired glucose metabolism (e.g. endothelial cell function). Prior
studies have not evaluated for associations between trajectories of circulating
microRNAs with trajectories of fasting blood glucose over time and the responses to
behavioral interventions to reduce risk. This study performed longitudinal assessment
of microRNAs and fasting blood glucose and identified relationships between
microRNAs and behavioral risk reduction interventions.
Methods
MicroRNAs (n = 353) were measured in subsets (n = 10, n = 8) of participants from
previously completed clinical trials that studied behavioral risk reduction interventions.
Fasting blood glucose trajectories were associated with changes in 45 microRNAs over
12 months.
Results
Following a 3-month physical activity and dietary intervention compared with baseline,
13 microRNAs were differentially expressed. Seven microRNAs (i.e. miR-106b,
miR-20b, miR-363, miR-486, miR-532, miR-92a and miR-93) were commonly identified
between the two analyses.
Conclusions
Further studies are needed to determine which microRNAs are prognostic biomarkers of
risk for type 2 diabetes versus consequences of impaired glucose metabolism. Additional
future directions of this research are to differentiate whether microRNAs are prognostic
and/or diagnostic biomarkers for risk for type 2 diabetes and predictive biomarkers of
responses to risk reduction interventions.
Keywords: biomarker, diabetes, fasting blood glucose, microRNA.
Introduction
Given the complex etiology, type 2 diabetes was recently
identified as a priority for the field of precision health (1). In
most people, risk for type 2 diabetes begins with insulin
resistance, which is largely undetectable in clinical
practice, and progresses to impaired fasting glucose
(i.e. fasting blood glucose 100–125 mg dL) before a
diagnosis of type 2 diabetes is made. During this prodro-
mal window prior to the diagnosis of type 2 diabetes,
harmful conditions (e.g. inflammation) can occur and go
largely undetected. (2,3) Common biomarkers (i.e. fasting
blood glucose and hemoglobin A1c) for type 2 diabetes
are used for diagnosis and monitoring of the disease but
do not identify which individuals are at greatest risk for
developing the disease in the prodromal window. Newer
© 2017 The Authors
Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice446
Obesity Science & Practice doi: 10.1002/osp4.134
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
biomarkers that provide prognostic information about risk
for type 2 diabetes have the potential to improve risk
stratification.
MicroRNAs are short (i.e. 18–26 nucleotide) regulatory
elements of translation of messenger RNAs to amino
acids. Extracellular circulating microRNAs found in serum
and plasma are easily measured in blood samples and are
potential biomarkers for risk for development of type 2
diabetes, showing changes in expression levels prior to
the onset of impaired glucose metabolism. (4,5). Because
microRNAs capture both underlying genetic risk and
responses to behavioral factors (e.g. diet and physical
activity) (6,7) they represent several potential biomarker
applications. First, as prognostic biomarkers, (8) there is
the possibility for improved granularity in detecting
glycaemic progression prior to the onset of type 2 diabe-
tes. Second, because microRNAs are associated with
individual pathways that singularly and collectively may
lead to type 2 diabetes, they are potentially diagnostic
biomarkers (8) that will provide greater understanding of
which pathways are activated in one individual.
Circulating microRNAs are also associated with compli-
cations (e.g. endothelial dysfunction) from impaired
glucose metabolism that precedes and characterizes
type 2 diabetes. (9,10)
Prior studies that evaluated relationships between
circulating microRNAs and risk for type 2 diabetes were
primarily limited to single measurements of microRNAs.
The cross-sectional design of prior studies limits determi-
nation of which microRNAs are potentially prognostic
biomarkers associated with trajectories of glucose
metabolism as opposed to complications from impaired
glucose metabolism. (11,12) The goals of this pilot study
were to generate preliminary data about microRNAs as
prognostic biomarkers by studying relationships between
the trajectories of individual microRNAs and trajectories
of fasting blood glucose over time. In addition, associa-
tions between risk factors (i.e. weight and fasting blood
glucose) for type 2 diabetes following a behavioral inter-
vention trial and circulating microRNAs are presented.
Research design and methods
Study participants
The previously completed Practicing Restorative Yoga vs.
Stretching for the Metabolic Syndrome (PRYSMS) study
(clinicaltrials.gov identifier NCT01024816) evaluated the
effects of restorative yoga versus active stretching on
blood glucose in community dwelling adults at risk for
type 2 diabetes. (13) Participants in PRYSMS were re-
cruited from the San Francisco and San Diego areas
and met the International Diabetes Federation criteria for
the metabolic syndrome. (14) Randomization was strati-
fied by sex and race/ethnicity. Participants (n = 171) were
randomized to either a restorative yoga or active
stretching intervention for 12 months. Both interventions
were delivered in a group setting twice weekly for
12 weeks and then weekly for 12 weeks and then monthly
for 24 weeks. Participants were asked to practice yoga or
stretching at home for at least 30 min three times per
week. Fasting blood glucose was measured at baseline
and every 3 months for the duration of the 1-year inter-
vention. Plasma was isolated from whole blood and
stored at 80°C.
Data from a recently completed randomized controlled
trial of a weight loss intervention in Filipino Americans (Fit
and Trim Trial) are also presented. The Fit and Trim study
was a randomized controlled trial of a physical activity
and diet lifestyle intervention for Filipino-Americans. The
purpose of the trial was to evaluate an adaptation of the
diabetes prevention program (15) that uses mobile-
persuasive technologies, cultural tailoring for Filipino-
Americans and a social networking component. Over
3 months, the program’s goals were for the participants
to lose 5% body weight, increase to and maintain
12,000 steps per day, reduce total fat intake to 25% of
daily calories and reduce sugar-sweetened beverages to
one every 2 weeks. A total of 62 participants, recruited
from the San Francisco Bay Area using community out-
reach strategies, completed the study. In this study, 3-h
oral glucose tolerance tests were performed at baseline.
After 3 months, fasting blood glucose and insulin were
measured. At both time points, plasma was isolated from
whole blood and stored at 80°C. We studied a random
subset (n = 8) of participants pre-intervention and
3-months post-intervention.
MicroRNA quantitation
The Firefly Bioworks Multiplex Circulating MicroRNA
Assay (Abcam Fireplex, Cambridge, MA, USA) was used
to quantify 353 microRNAs from plasma at four time
points in a random subset of participants (n = 10) strati-
fied by sex and intervention group from the PRYSMS
study. The same assay was used to measure microRNAs
from plasma from an additional random subset of partici-
pants (n = 8) stratified by sex and intervention group from
the Fit and Trim study. This assay performs direct detec-
tion of microRNAs from plasma without an isolation step.
Statistical analysis
Descriptive statistics were calculated using means and
standard deviations to evaluate demographic and clinical
characteristics of participants in the PRYSMS and Fit and
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Trim studies and comparisons between groups used
Student’s t-test (Stata version 13, College Station, TX).
The secondary analysis of the PRYSMS study focused
on changes in fasting blood glucose over time. In order to
identify patterns of fasting blood glucose in the PRYSMS
sample (n = 171) (Figure 1), growth mixture modelling
(GMM) was performed. GMM is an extension of latent
growth curve analysis that extends the estimation of a
single growth curve – represented as latent variables:
intercept and slope coefficients and variance
components for them – to the estimation of a new latent
categorical variable that identifies latent growth curves
for two or more classes. (16–19) The model fit for the
GMM was assessed statistically by identifying the model
with the lowest Bayesian Information Criterion and by
testing the ‘K’ versus ‘K-1’ class models to determine
whether a model with K classes fit the data better than a
model with K-1 classes with the Vuong–Lo–Mendell–
Rubin likelihood ratio test. (17,20,21) Two phenotypic
groups (i.e. latent classes) from five glucose measure-
ments over 1 year were identified (Figure 2, panel A)
(Mplus Version 7.4). One GMM group exhibited variable
blood glucose and the other group stable blood glucose.
The study described here included a subset (n = 10) of
participants randomly selected with equal distribution
between the GMM groups and across the restorative
yoga and active stretching groups. Trajectories of fasting
blood glucose for this subset of participants are shown in
Figure 2, panel B.
Expression of individual microRNAs was normalized
using the global geometric mean signal of all reliably
detected microRNAs in the assay.
Repeated measures analysis of variance was used to
determine which microRNAs changed over time between
the variable and stable glucose groups in the PRYSMS
study (Stata v 14.2, College Station, TX). The false
discovery rate method (22) at a threshold of 0.1 was used
to adjust the significance levels and identify significant
A B
Figure 1 Panel A shows the predicted and actual trajectories of fasting blood glucose in the variable (short dashed line and solid black line,
respectively) and stable (long dashed line and solid grey line, respectively) growth mixture modeling classes over 12 months. Panel B shows
the fitted trajectories of fasting blood glucose for individual participants included in the study.
Figure 2 MicroRNAs (miRs) associated with risk for type 2 diabetes were identified in the Practicing Restorative Yoga vs. Stretching for the
Metabolic Syndrome trial. MicroRNAs associated with response to a behavioral intervention were identified in the Fit and Trim weight loss trial.
All microRNAs shown were measured in both studies.
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changes over time. Linear models were used to determine
whether the trajectories of individual microRNAs were
statistically significantly positive or negative or were vari-
able compared with trajectories of fasting blood glucose.
In the Fit and Trim study, paired Student’s t-tests were
used to compare differences in individual microRNAs be-
fore and after the 3-month physical activity and dietary in-
tervention. Pearson’s correlation coefficients were
calculated to determine associations between baseline
levels of individual microRNAs and weight change after
3 months and between changes in individual microRNAs
and weight change over 3 months.
Results
The subset of participants from the PRYSMS trial in-
cluded in this study was equally distributed by sex and
had a mean age of 57 ± 4 years. Clinical characteristics
at baseline between the two glucose classes are shown in
Table 1. Overall, the variable blood glucose group had a
mean increase in fasting blood glucose after 12 months
of 2.2 mg dL1 compared with no change in the stable
blood glucose class. Forty-five individual microRNAs were
differentially expressed between the GMM groups over
1 year (p< 0.05) (Table 2). Of these, the overall trajectories
were positive for one microRNA (i.e. miR-320c) and nega-
tive for threemicroRNAs (i.e. miR-22, miR-372 andmiR-339)
in the variable glucose group and negative for onemicroRNA
(i.e. miR-423) in the stable glucose group. For the remaining
statistically significant microRNAs, the trajectories were
variable (i.e. polynomial) across the five time points.
Clinical characteristics of the Fit and Trim subset of
participants, included in this study, are shown in
Table 3. The mean weight loss after the intervention
was 9 ± 4 lb. This represented a 4.8% weight loss
following the intervention. In these eight participants, a
total of 13 microRNAs were differentially expressed after
the weight loss intervention (p < 0.1). Four (i.e. miR-326,
miR-24, miR-425 and miR-652) exhibited increased
expression after the 3-month intervention. The remaining
nine (i.e. miR-106b, miR-140, miR-20b, miR-363, miR-
486, miR-532, miR-92a, miR-93 and miR-let7c) exhibited
decreased expression after the intervention. Seven
Table 1 Clinical characteristics of participants in the Practicing
Restorative Yoga vs. Stretching for the Metabolic Syndrome trial
(n = 10).
Stable blood
glucose class
Variable blood
glucose class p-value
Body mass index
(kg m2)
32.6 ± 6.7 35.0 ± 5.5 0.39
Weight (lb) 205 ± 41 224 ± 31 0.26
Total cholesterol (mg dL1) 218 ± 39 193 ± 38 0.16
LDL-c (mg dL1) 131 ± 34 108 ± 33 0.14
HDL-c (mg dL1) 53 ± 9 47 ± 14 0.27
Triglycerides (mg dL1) 167 ± 70 187 ± 90 0.63
Fasting blood glucose
(mg dL1)
95 ± 8 117 ± 11 <0.001
Hemoglobin A1c (%) 5.6 ± 0.4 6.5 ± 0.6 <0.05
HDL-c, high-density lipoprotein cholesterol; LDL-c, low density
lipoprotein cholesterol.
Table 2 MicroRNAs differentially expressed between the variable
and stable blood glucose groups in the practicing Restorative Yoga
vs. Stretching for the Metabolic Syndrome trial
MicroRNA p-value
miR-20a-5p <0.001
miR-22-3p <0.001
miR-320c <0.001
miR-320e <0.001
miR-92a-3p <0.001
miR-93-3p <0.001
miR-17-5p 0.001
miR-320a 0.001
miR-320b 0.001
miR-342-3p 0.001
miR-497-5p 0.001
miR-93-5p 0.001
miR-15b-3p 0.003
miR-185-5p 0.003
miR-183-3p 0.004
miR-423-5p 0.005
let-7b-5p 0.007
miR-20b-5p 0.007
miR-29a-3p 0.007
miR-106b-5p 0.009
miR-15a-5p 0.009
miR-214-3p 0.011
miR-29b-3p 0.011
miR-106a-5p 0.014
miR-194-5p 0.017
miR-320d 0.017
let-7g-5p 0.020
miR-424-5p 0.021
miR-660-5p 0.024
let-7i-5p 0.026
miR-363-3p 0.026
miR-92b-3p 0.027
miR-181c-3p 0.028
miR-532-3p 0.029
miR-1237-3p 0.030
miR-32-5p 0.031
miR-372-3p 0.031
miR-98-5p 0.031
miR-29c-3p 0.032
miR-503-5p 0.032
miR-30d-5p 0.035
miR-615-5p 0.040
miR-25-3p 0.042
miR-339-3p 0.046
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microRNAs overlapped with the PRYSMS findings (i.e.
miR-106b [fold change 0.73, p < 0.1], miR-20b [fold
change 0.80, p < 0.05], miR-363 [fold change 0.66,
p < 0.1], miR-486 [fold change 0.72, p < 0.1], miR-532
[fold change 0.75, p < 0.05], miR-92a [fold change 0.81,
p < 0.1] and miR-93 [fold change 0.84, p < 0.1]) (Figure 1).
Changes in levels of three microRNAs (i.e. miR-146a,
miR-151a and miR-23a levels) were very strongly posi-
tively correlated (r2 > 0.8, p < 0.05) with changes in
weight over 3 months. An additional nine microRNAs
(i.e. miR-181b, miR-181d, miR-21, miR-221, miR-222,
miR-223, miR-23, miR-24 and miR-27b) were strongly
positively correlated (0.6 < r2 < 0.8, p < 0.05) with
weight change. Baseline levels of eight microRNAs (i.e.
miR-143, miR-145, miR-146, miR-191, miR-221, miR-
23a, miR-29a and miR-584) have a positive association
with weight change after 3 months (r2 > 0.6, p < 0.05).
There were no negative associations between baseline
levels of individual microRNAs or change in levels of indi-
vidual microRNAs with weight change over 3 months.
Conclusion
MicroRNAs are emerging as possible prognostic bio-
markers to identify individuals at high risk for type 2 dia-
betes, and diagnostic biomarkers to characterize
individual differences in disease etiology. A limitation of
prior studies is the inability to differentiate circulating
microRNAs related to risk for type 2 diabetes versus
complications of type 2 diabetes. In this study, numerous
circulating microRNAs with trajectories that relate to
trajectories of fasting blood glucose were identified.
Prior observational studies on microRNAs associated
with risk for type 2 diabetes have been primarily cross-
sectional or limited to two measures of fasting blood
glucose or related markers. (11,12,23–25) A few prior
studies included repeated measures of microRNAs that
were pre-post interventions that target pathways associ-
ated with risk for type 2 diabetes (e.g. exercise). (6,7,24)
One of the early contributions in this field identified
microRNAs associated with prevalent type 2 diabetes af-
ter 10 years in a large cohort study of Europeans. (23)
Among the microRNAs identified was miR-126, which is
now well established to be an endothelial-related
microRNA (26) and possibly related to complications from
type 2 diabetes as opposed to mechanisms underlying
development of the primary disease (9,10,27). There are
potentially useful biomarker applications for microRNAs
related to complications, but these are discrete from ap-
plications for microRNAs associated with prodromal
identification of risk for type 2 diabetes.
This pilot study provided preliminary evidence for 45
potential prognostic microRNA biomarkers with trajecto-
ries over 1 year that associate with trajectories of fasting
blood glucose. Among these are numerous microRNAs
that were previously identified in our own and other prior
studies. For example, miR-106b, miR-17, miR-20a and
miR-93 are related to a measure of insulin resistance,
(28) miR-214, miR-22 and miR-320a are related to insulin
resistance and responses to thiazolidenidones (4) and
miR-15a, miR-320a and miR-423 are related to glycaemic
impairment and progression (5). The latter two, miR-320a
and miR-423, have also been reported in other studies
with related mechanisms. (29,30) A future potential appli-
cation of microRNAs is as predictive biomarkers (8) to
optimize risk reduction interventions. Preliminary work
from our group identifies microRNAs that are also
associated with behavioral interventions like weight loss
in response to a physical activity and diet intervention
(e.g. Fit and Trim trial presented as confirmatory data).
Taken together, these are promising preliminary data to
show that microRNAs are antecedent markers for risk
for type 2 diabetes before the development of impaired
glucose metabolism and type 2 diabetes (i.e. prognostic
and diagnostic biomarkers) and microRNAs may be
useful for predicting responses to interventions (i.e. pre-
dictive biomarkers). A summary of preliminary data shows
some microRNAs show overlap as prognostic and
diagnostic biomarkers for risk for type 2 diabetes and
predictive biomarkers for responses to interventions,
while others are unique (Figure 1).
This study provided preliminary data from a hypothesis
generating pilot study. Future studies are needed in three
key areas. The first is to validate prognostic biomarker
applications of microRNAs in larger samples and to
investigate whether clusters of related microRNAs might
enhance risk prediction. Second is to further investigate
microRNAs as diagnostic biomarkers by identification of
Table 3 Clinical characteristics of participants in the Fit and Trim trial
(n = 8).
Baseline 3 Months Change
Body mass index (kg m2) 30.5 ± 2.8 28.9 ± 3.4 1.5 ± 0.8
Weight (lb) 180 ± 32 172 ± 35 9 ± 4
Total cholesterol (mg dL1) 187 ± 31 173 ± 31 14 ± 31
LDL-c (mg dL1) 103 ± 20 97 ± 22 5 ± 10
HDL-c (mg dL1) 48 ± 12 49 ± 9 1 ± 6
Triglycerides (mg dL1) 208 ± 176 155 ± 150 55 ± 186
Fasting blood glucose (mg dL1) 85 ± 4 83 ± 5 2 ± 3
T120 blood glucose (mg dL1) 109 ± 37 n/a n/a
Hemoglobin A1c (%) 5.6 ± 0.2 5.5 ± 0.2 0.1 ± 0.2
Fasting insulin (μIU mL1) 4.8 ± 3.5 5.6 ± 1.9 0.8 ± 2.2
HDL-c, high-density lipoprotein cholesterol; LDL-c, low density
lipoprotein cholesterol; n/a, not assessed.
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mechanistic targets of microRNAs so that underlying
pathways can be identified. This will facilitate improved
risk stratification and targeted treatments. Third is to
expand on preliminary research on microRNAs as
predictive biomarkers that predict responses to risk
reduction interventions in order to optimize treatment
strategies for individuals.
This preliminary study has limitations, including a small
sample size and moderate differences in fasting blood
glucose between groups. Despite these limitations, a
large number of microRNAs that were significantly asso-
ciated with trajectories of fasting blood glucose after
adjusting for multiple comparisons were identified. These
findings support the need for future studies in larger sam-
ples sizes with greater power to model clusters of
microRNAs. MicroRNAs may become useful prognostic,
diagnostic and predictive biomarkers for prevention and
treatment of type 2 diabetes.
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